



MAY 3 0 2002

RECEIVED

JUN 04 2002

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


Sheet 1 of 23

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/037,555
(use as many sheets as necessary)		Filing Date	01/03/2002
		First Named Inventor	Norbert HAUER
		Art Unit	1626
		Examiner Name	R. Ramsauer
Sheet	1	of	3
		Attorney Docket Number	5/1265-1-D1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵ (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		EP 0 511 477 A1 WO 99 07669 A1	11/04/1992 02/18/1999	Kyowa Hakko Kogyo Am. Home Prod. Corp.

Examiner Signature		Date Considered	2-10-03
-----------------------	---	--------------------	---------

1. Applicant's unique citation designation number (optional). 2. See *Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 3. Enter Office that issued the document by the two-letter code (WIPO Standard 3.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the document.*

O I P E
MAY 3 0 2002
PATENT & TRADEMARK OFFICE

RECEIVED

JUN 04 2002

TECH CENTER 1600/1900

Approved for use through 10/31/2002 GMD Reference

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

Complete If Known

Application Number	10/037,555
Filing Date	01/03/2002
First Named Inventor	Norbert HAUEL
Group Art Unit	1628
Examiner Name	R. Ramsauer
Attorney Docket Number	5/1265-1-D1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Database WPI Sec. Ch. Week 199416, Derwent Pub. Ltd., London, GB; Class B05, AN 1994-128759; XP002186009	
		Database WPI Sec. Ch. Week 198537, Derwent Publ. Ltd., London, GB; Class B05, AN 1985-226638; XP002186010	
		Database WPI Sec. Ch. Week 198528, Derwent Pub. Ltd., London, GB; Class B03, AN 1985-168505; XP 002186011	
		YASHIRO, ET AL; "Tranlast (N-(3,4-dimethoxycinnamoyl) Anthranilic Acid) Down-Regulates the Growth of Scirrhous Gastric Cancer"; Anticancer Res., Bd. 17, Nr. 2a, 1997, 895-900	
		RALPH, ET AL; "Inhibitors of lipoxygenase have antiproliferative effects on P815 murine mastocytoma cells"; Cancer Lett. (Shannon, Ire.) 1990, 49(3), 181-5	
		NIE, ET AL; "Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca2+-permeable channel"; Cell Calcium, Bd. 22, Nr. 2, 1997, 75-82	
		LIU, Y. ET AL; "Synthesis and antiinflammatory activity of (E)-4-cinnamolyloxy styrene derivatives", Zhongguo Yaowu Huaxue Zazhi (Chinese Journal of Medicinal Chemistry), Bd 9, Nr. 3, 1999, 186-191	
		NISHIZAWA, Y. ET AL; "Effects of antiallergic drugs on the proliferation of estrogen-sensitive mouse Leydig cell line"; Anticancer Res., Bd 19, Nr. 3A, 1996, 1241-1245	
		MURAHASHI, K. ET AL; "The combination therapy of scirrhous gastric carcinoma with tranlast and cisplatin"; Proc. of the Am. Assn. for Cancer Res. Annual, Bd 39, 1998, 308	
		BECKMAN, ET AL; "Phospholipid peroxidation in tumor promoter-exposed mouse skin"; Carcinogenesis, Bd 15, Nr. 12, 1994, 2937-2944	
		MURAHASHI K. ET AL; "Tranlast, a fibroblasts inhibitor, inhibits the metastasis of gastric cancer cells", Proc. of the Am. Assn. for Cancer Res. Annual, Bd 40, 1999, 704	<input checked="" type="checkbox"/>

Examiner
Signature

Re

Date
Considered

2-10-03

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or suggestions concerning the time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

O I P E
S C I O
MAY 30 2002
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

RECEIVED

JUN 04 2002

Approved for use through 10/31/2008 under PTO-910. GPO: 2000-1600-2000
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1446B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/037,555
Filing Date	01/03/2002
First Named Inventor	Norbert HAUEL
Group Art Unit	1626
Examiner Name	R. Ramsuer
Attorney Docket Number	5/1265-1-D1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ISAJI, M. ET AL; "Tranlast Inhibits the Proliferation, Chemotaxis and Tube Formation of Human Microvascular Endothelial Cells In Vitro and Angiogenesis In Vivo"; British Journal of Pharmacology. Bd. 122, Nr. 6, 1997, 1061-1066 KUMAZAWA, T. ET AL; "(E)-4-(2-[[3-(Indol-5-yl)-1-oxo 2-butenyl]amino]phenoxy)butyric Acid Derivatives; A New Class of Steroid 5 alpha-Reductase Inhibitors in the Rat Prostate.. 1"; J. Med. Chem. Bd. 38, Nr. 15, 1995, 2887-2892	

Examiner
Signature



Date
Considered

2-10-03


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you spent to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/037,555
(use as many sheets as necessary)		Filing Date	01/03/2002
		First Named Inventor	Norbert HAUEL
		Group Art Unit	1626
		Examiner Name	R. Ramsuer
Sheet	3	of	3
		Attorney Docket Number	
		5/1265-1-D1	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Signature:  Date Considered: 2-10-07

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete the form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20311. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20311.